Digital Model Based on Noninvasive Factors Shows Accuracy for Identifying IBD in Children
By Lori Solomon HealthDay Reporter

TUESDAY, July 22, 2025 -- A model based on noninvasive tests shows high accuracy as a digital tool for the rapid identification of children with inflammatory bowel disease (IBD), according to a study published online July 12 in the Journal of Inflammation Research.
Hailin Wu, from the Children's Hospital of Fudan University in Shanghai, and colleagues sought to establish and validate the optimal model of noninvasive evaluation tests to help clinicians with the early identification of pediatric IBD. The analysis included data on noninvasive features from 314 pediatric patients (IBD, 103 participants; non-IBD, 211 participants).
The researchers found that the ultrasound feature of Limberg level >1 (bowel wall thickening with blood flow) was identified as the most valuable feature, followed by the erythrocyte sedimentation rate, fecal calprotectin, C-reactive protein, and hypoalbuminemia. For clinical symptoms, the most valuable feature was active perianal abscess or fistula. Based on these features, the model showed high accuracy and robustness in both internal validation (area under the curve, 0.97) and temporal external validation (area under the curve, 0.94).
"We developed a model based on rapid, simple, and cost-effective noninvasive tests and demonstrated its potential as a digital tool for the early identification of children with IBD," the authors write. "Importantly, it is designed to complement, not replace, endoscopic evaluation."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-07-23 06:00
Read more

- Moderna’s New Flu Shot Shows Strong Results in Older Adults
- FDA Will Now Require Labeling of ADHD Medication to Indicate Weight Loss Risk
- Shorter-Form Messaging May Be Preferable for Trial Recruitment
- FDA Plans to Revoke 52 Food Standards
- Insurers Promise to Speed Up Delays in Health Care Approvals
- Long-Term Stroke Risk Higher for Women With Pregnancy Complications
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions